How is tolvaptan dosed and monitored for autosomal dominant polycystic kidney disease and hyponatraemia, and what are its contraindications and adverse effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Tolvaptan: Dosing, Monitoring, Contraindications, and Adverse Effects

For ADPKD, initiate tolvaptan at 45 mg upon waking and 15 mg 8 hours later, titrating weekly to a target of 90 mg AM/30 mg PM based on tolerability, with mandatory monthly liver function monitoring for 18 months, then every 3 months thereafter. 1

Dosing for ADPKD

Initial Dosing

  • Starting dose: 45 mg in the morning upon waking + 15 mg 8 hours later 1
  • Begin on a non-working day to allow patients to observe and adapt to aquaretic effects 2

Titration Schedule

  • Week 1+: Increase to 60 mg AM + 30 mg PM
  • Week 2+: Increase to target dose of 90 mg AM + 30 mg PM
  • Titrate at intervals ≥1 week based on patient tolerability 1
  • Continue treatment until approaching kidney replacement therapy 1

Dose Adjustments

Hold or downtitrate tolvaptan for: 1

  • Concurrent CYP3A inhibitors (strong: itraconazole, ketoconazole, clarithromycin, ritonavir; moderate: fluconazole, erythromycin, diltiazem, verapamil, grapefruit juice)
  • Intolerance or side effects
  • Elevated liver enzymes

Skip doses when at risk of volume depletion: 1

  • Limited water access
  • Increased fluid losses (vomiting, diarrhea)
  • Activities in warm weather
  • Any "sick day" scenario

Treatment Duration

  • Can continue in patients >55 years and/or eGFR <25 mL/min/1.73 m² if well tolerated 1

Dosing for Hyponatremia

This formulation (generic tolvaptan tablets) is contraindicated for ADPKD outside FDA-approved REMS due to hepatotoxicity risk. 3

For hyponatremia (hypervolemic/euvolemic):

  • Starting dose: 15 mg once daily
  • Titration: Increase to 30 mg, then maximum 60 mg once daily at intervals ≥24 hours
  • Duration limit: Maximum 30 days to minimize liver injury risk 3
  • Must initiate and re-initiate in hospital with close serum sodium monitoring 3

Monitoring Requirements

Liver Function Tests (ADPKD)

Mandatory monitoring schedule: 1, 2

  • Monthly for first 18 months
  • Every 3 months thereafter until discontinuation
  • Obtain morning blood samples before tolvaptan dose

Management of Liver Enzyme Elevations

If AST/ALT ≥3× ULN or >2× baseline (even if <2× ULN): 1

  1. Hold tolvaptan immediately
  2. Repeat LFTs within 48-72 hours
  3. Assess for other etiologies

If AST/ALT >2× ULN with symptoms (fatigue, nausea, vomiting, anorexia, right upper quadrant pain, fever, rash, jaundice, pruritus, abdominal distention): 1

  • Hold tolvaptan immediately
  • Follow same algorithm as above

Permanent discontinuation required if: 1

  • Transaminases remain ≥3× ULN on repeat testing
  • No alternative explanation for liver injury identified
  • Per U.S. label: Do not restart if AST/ALT >3× ULN with signs/symptoms of hepatic injury

Rechallenge considerations: 1

  • May consider after LFTs normalize in patients with mild transaminase elevations
  • Requires increased monitoring frequency

Other Monitoring

  • Serum sodium: Provides insight into adequacy of water intake 1
  • Serum potassium: Monitor in patients with K+ >5 mEq/L or on drugs that increase potassium 3
  • eGFR: Expect small, reversible reduction (up to 10%) reflecting impact on compensatory hyperfiltration 1, 2

Contraindications

Absolute Contraindications 3

  1. ADPKD treatment outside FDA-approved REMS (for generic formulation)
  2. Unable to sense or respond to thirst
  3. Hypovolemic hyponatremia
  4. Concurrent strong CYP3A inhibitors
  5. Anuria
  6. Hypersensitivity to tolvaptan (anaphylactic shock, generalized rash)

Relative Contraindications/Cautions

  • Underlying liver disease (avoid use) 3
  • Severe malnutrition, alcoholism, advanced liver disease (risk of osmotic demyelination) 3
  • Pregnancy (may cause fetal harm) 3

Adverse Effects

Most Common (Aquaretic Effects)

Occur in majority of patients due to mechanism of action: 1, 2

  • Polyuria/pollakiuria: Averaging 5-7 L/day urine output
  • Thirst: 7.7-40.3% of patients
  • Dry mouth: 4.2-23.0% of patients
  • Nocturia: Significant impact on sleep and quality of life
  • Effects begin 1-2 hours post-dose, peak at 4-8 hours, resolve within 24 hours of withdrawal 2

Serious Adverse Effects

Idiosyncratic Drug-Induced Liver Injury (IDILI): 1, 4

  • Incidence: ~5% develop transaminases >3× ULN (vs. 1% placebo)
  • Timing: Most often during first 18 months
  • Resolution: Within 1-4 months after cessation
  • Severe cases: Rare acute liver failure requiring transplantation reported 2, 3

Osmotic Demyelination Syndrome (for hyponatremia indication): 3

  • Risk with too-rapid sodium correction (>12 mEq/L/24 hours)
  • Manifests as dysarthria, mutism, dysphagia, lethargy, spastic quadriparesis, seizures, coma, death
  • Higher risk in severe malnutrition, alcoholism, advanced liver disease

Other Adverse Effects: 1

  • Hyperuricemia and rarely gout
  • Hyperkalemia (especially with RAAS inhibitors) 2
  • Dehydration/hypovolemia requiring intervention

Real-World Discontinuation Rates

  • 23-29% discontinuation over 1-8 years in observational studies 2
  • Primary reasons: aquaretic intolerance (4.2%), hepatic adverse events (2.1%), lifestyle impact

Patient Counseling Essentials

Fluid Management 1, 2

  • Drink liquids without sugar or fat to replace urinary losses
  • Adopt low-sodium intake (reduces polyuria)
  • Avoid fluid restriction during first 24 hours
  • Drink 1-2 glasses before bedtime and with each nocturia episode
  • Proactively drink water throughout day to prevent dehydration symptoms (headache, lethargy, fatigue, dizziness)

Lifestyle Adaptations 2

  • Plan daily schedules around frequent urination
  • Identify accessible restrooms at work/public spaces
  • Most patients adapt within days to months
  • Encourage optimistic mindset about tolerability

Sick-Day Plan 1

Skip doses during:

  • Limited water access
  • Increased fluid losses (vomiting, diarrhea)
  • Warm weather activities
  • Any volume depletion risk

Clinical Efficacy (ADPKD)

Evidence from TEMPO 3:4 and REPRISE trials: 1, 2

  • Slows eGFR decline by 1.3 mL/min/1.73 m²/year
  • Reduces total kidney volume growth by 2.7% annually
  • Decreases UTI, kidney stones, hematuria, and kidney pain events
  • Real-world data shows slowed TKV growth (6.58% to 3.71%/year) 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.